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Abstract
 
Natural killer (NK) T cells recognize lipid antigens in the context of the major histocompati-
bility complex (MHC) class 1–like molecule CD1 and rapidly secrete large amounts of the cy-
tokines interferon (IFN)-
 
 
 
 and interleukin (IL)-4 upon T cell receptor (TCR) engagement.
We have asked whether NK T cell activation influences adaptive T cell responses to myelin
antigens and their ability to cause experimental autoimmune encephalomyelitis (EAE), a model
for multiple sclerosis. While simultaneous activation of NK T cells with the glycolipid 
 
 
 
-galac-
tosylceramide (
 
 
 
-GalCer) and myelin-reactive T cells potentiates EAE in B10.PL mice, prior
activation of NK T cells protects against disease. Exacerbation of EAE is mediated by an en-
hanced T helper type 1 (Th1) response to myelin basic protein and is lost in mice deficient in
IFN-
 
 
 
. Protection is mediated by immune deviation of the anti-myelin basic protein (MBP)
response and is dependent upon the secretion of IL-4. The modulatory effect of 
 
 
 
-GalCer re-
quires the CD1d antigen presentation pathway and is dependent upon the nature of the NK T
cell response in B10.PL or C57BL/6 mice. Because CD1 molecules are nonpolymorphic and
remarkably conserved among different species, modulation of NK T cell activation represents a
target for intervention in T cell–mediated autoimmune diseases.
Key words: NK T cells • CD1d • experimental autoimmune encephalomyelitis • 
immunotherapy • 
 
 
 
-galactosylceramide
 
Introduction
 
Innate pathways of immunity are crucial in the upregula-
tion of costimulatory molecules on antigen presenting cells
as well as in providing an initial cytokine milieu necessary
for the development of acquired immunity. NK T cells
that rapidly secrete cytokines can influence the outcome of
immune responses, not only in infectious but also in au-
toimmune diseases. NK T cells recognize lipid antigens in
the context of CD1d molecules, which are nonpolymor-
phic, MHC class I like, and 
 
 
 
2-microglobulin dependent
(1, 2). The CD1 proteins are encoded by five distinct genes
(isotypes) and can be categorized into two groups: group 1
comprises CD1a, CD1b, and CD1c and is present in hu-
mans but not in rodents. Group 2, the CD1d molecule, is
primarily expressed by dendritic cells, macrophages, subsets
of B cells, thymocytes, and by hepatocytes. CD1e does not
belong to either group and may not be functional. Human
and murine CD1d share significant sequence homology (1,
2). The main T cell subset associated with CD1d recogni-
tion is the NK T cells, most of which express a TCR en-
coded by an invariant TCR 
 
 
 
 chain (formed by a V
 
 
 
14-
J
 
 
 
18 rearrangement in mice and a homologous V
 
 
 
24-J
 
 
 
15
rearrangement in humans.) The invariant V
 
 
 
 is coex-
pressed with one or a few V
 
 
 
s, although in mice these have
very diverse CDR3 regions (3–5).
Activation of NK T cells in vivo promptly induces acti-
vation of both innate and adaptive responses and induces ac-
tivation of NK cells, dendritic cells, T cells, and B lympho-
cytes, a characteristic of strong adjuvants. Upon activation,
NK T cells also secrete large amounts of cytokines charac-
teristic of both type 1 (IFN-
 
 
 
) and type 2 (IL-4, IL-13) re-
sponses (1, 2). Thus, NK T cells have been implicated in
various immune responses: in protection against pathogens,
 
such as 
 
Leishmania major
 
 (6); in tumor immunity (7–9); in
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tolerance associated with the anterior chamber of eye and
tissue grafts (10, 11); and in autoimmunity (12–23). The
number as well as cytokine phenotype of NK T cells is al-
tered in several autoimmune experimental animals as well as
in humans with diabetes or multiple sclerosis.
 
 
 
-galactosylceramide (
 
 
 
-GalCer),
 
*
 
 a glycolipid origi-
nally isolated from a marine sponge, is recognized by
nearly all the mouse and human NK T cells with invariant
 
 
 
 chain TCR rearrangements (3–5). 
 
 
 
-GalCer is a potent
activator of NK T cells both in vivo and in vitro. Recently
it has been suggested that the recognition of autologous
lipids rather than microbial ligands is the primary func-
tion of CD1d-restricted T cells (24). Although CD1d-
restricted self-antigens have not yet been identified, several
observations suggest that CD1d-reactive T cells are au-
toreactive and that they exhibit the phenotype of activated
memory cells (1, 25). In vivo activation of V
 
 
 
14 NK T
cells by administration of 
 
 
 
-GalCer in C57BL/6 mice, re-
sults in the polarization of adaptive immune response to-
ward Th2 (26, 27).
EAE is a prototypic CD4 T cell–mediated autoimmune
disease, characterized by inflammation and demyelination
in the central nervous system accompanied by paralysis fol-
lowing immunization with myelin antigens, for example
myelin basic protein (MBP) and myelin oligodendrocyte
protein (MOG). EAE is considered to be an instructive
model for the human demyelinating disease multiple scle-
rosis (MS) because they both share many pathological and
immune dysfunctions (28). A majority of the MBP-primed
effector CD4 T cells which mediate EAE in B10.PL mice
recognize the NH
 
2
 
-terminal peptide MBPAc1–9 and pre-
dominantly use the TCR V
 
 
 
8.2 gene segment (29, 30).
Generally EAE is transitory or monophasic in B10.PL
mice, and most mice spontaneously recover following ex-
pansion of regulatory CD4 and CD8 T cells recognizing
distinct determinants on the V
 
 
 
8.2 chain (31–34). Al-
though the regulation and function of individual cytokines
is complex, most experimental observations are consistent
with the idea that myelin antigen-reactive Th1 cells are en-
cephalitogenic whereas the antigen-reactive Th2 response
is protective (35–37). Th1 cells secrete IL-2 and IFN-
 
 
 
,
whereas Th2 cells secrete IL-4, IL-5, IL-10, and IL-13.
Here we have examined the effect of activation of NK T
cells by 
 
 
 
-GalCer on the response to myelin antigens and
on the course of EAE in B10.PL and in C57BL/6 mice.
Our findings demonstrate that the timing of activation of
NK T cells by 
 
 
 
-GalCer has a dramatic effect on the cy-
tokine secretion profile of MBP-reactive T cells as well as
on the clinical course of EAE. While coimmunization of
lipid with myelin antigens potentiates disease in B10.PL
mice, it prevents EAE in C57BL/6 mice. However, prior
immunization prevents EAE in both strains. Using IFN-
 
 
 
 
 
/
 
 
 
 mice and IL-4–depleted mice, we show here that
 
these cytokines are involved in the 
 
 
 
-GalCer–mediated
modulation of disease. Furthermore 
 
 
 
-GalCer immuniza-
tion does not influence EAE in CD1d-deficient mice.
These data suggest that appropriate activation of invariant
NK T cells provides a useful target for intervention in au-
toimmune demyelinating diseases.
 
Materials and Methods
 
Mice.
 
Female B10.PL and C57BL/6 mice were purchased
from The Jackson Laboratory. C57BL/6.CD1d
 
 
 
/
 
 
 
 mice were
originally generated in the laboratory of Dr. L. Van Kaer.
B10.PL.CD1d
 
 
 
/
 
 
 
 
 
and B10.PLCD1d
 
 
 
/
 
 
 
 mice were bred in our
colony. B10.PL.IFN-
 
 
 
 
 
/
 
 
 
 mice were obtained from the labora-
tory of Dr. Garrison Fathman (Stanford University, Stanford,
CA) and bred in our colony. All mice were maintained under
specific pathogen-free conditions at the vivarium of the La Jolla
Institute for Allergy and Immunology (LIAI).
 
Reagents.
 
MBP was purified from guinea pig brains and
spinal cords, as described previously (38). MBPAc1–9 (Ac-
ASQKRPSQR) was synthesized in our own facility at LIAI.
MOG peptide 35–55 (MEVGWYRSPFRVVHLYRNGK) was
synthesized by the Biopolymer Facility at Harvard Medical
School (Boston, MA). Glycolipids, 
 
 
 
-GalCer or KRN7000 and
 
 
 
-GalCer were synthesized by the Pharmaceutical Research Lab-
oratory of Kirin Brewery Co. (Gunma, Japan) as described previ-
ously (3). A stock solution of 
 
 
 
-GalCer or 
 
 
 
-GalCer was diluted
to 220 
 
 
 
g/ml in 0.5% polysorbate-20 and 0.9% NaCl (vehicle).
PE-labeled mouse CD1d tetramer complexes loaded with 
 
 
 
-Gal-
Cer were generated as described (39).
 
Flow Cytometry Analysis.
 
For the in vivo activation/depletion
of NK T cells, mice were injected intravenously with 4.4 
 
 
 
g of
 
 
 
-GalCer in 200 
 
 
 
l PBS or an equivalent volume of PBS, and
liver mononuclear cells and splenocytes were collected for stain-
ing after 4 h. Cell suspensions (10
 
6
 
) were stained for various NK
T cell markers using either PE-labeled mCD1d tetramer loaded
with 
 
 
 
-GalCer or unloaded, or PE-labeled anti-NK1.1 (clone
PK136) in combination with FITC-labeled anti-TCR V
 
 
 
(clone H57–597), anti-V
 
 
 
8.1/8.2 (clone MR5–2), anti-V
 
 
 
7
(clone TR310), and anti-V
 
 
 
2 clone (B10.6). After staining the
cells were analyzed by flow cytometry using the FACScan™ with
CELLQuest™ software (BD PharMingen). All antibodies were
purchased from BD PharMingen.
 
Measurement of NK T Cell Response to 
 
 
 
-GalCer.
 
For prolif-
erative response to 
 
 
 
-GalCer, splenocytes were collected at days
3, 5, and 10 after lipid administration and cultured in vitro in the
presence of 100 ng/ml of 
 
 
 
-GalCer. Proliferation was deter-
mined by incorporation of [
 
3
 
H]thymidine as described earlier
(31). For comparison of the proliferative and cytokine secretion
profiles, splenocytes from naive B10.PL, C57BL/6, and C57BL/
6.CD1d
 
 
 
/
 
 
 
 mice were used in the presence of different concen-
trations of the glycolipid. Supernatants from 14 or 48 h cultures
were used in ELISA assays to measure cytokine secretion as de-
scribed previously (40).
 
Measurement of Myelin Antigen-specific Proliferative Response and
Cytokine Secretion.
 
For the measurement of response to MBP or
MOG peptides, mice were immunized subcutaneously with 100
 
 
 
g of MBPAc1–9 or MOG35–55 emulsified in CFA. 
 
 
 
-GalCer
was injected intraperitoneally either at the same time in a coim-
munization or 1 wk earlier in the preimmunization protocol.
Lymph nodes or spleens of mice were removed after 9–10 d.
Lymph node cells (5 
 
 
 
 10
 
5
 
/well) and splenocytes (8 
 
 
 
 10
 
5
 
/well)
 
*
 
Abbreviations used in this paper:
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were cultured with the indicated peptides in HL-1 media (Hy-
clone) supplemented with 50 
 
 
 
M 2-ME (Sigma-Aldrich), 0.1 U
penicillin-streptomycin (Life Technologies), and 2 mM L-glu-
tamine. After 14 or 48 h the culture supernatants were collected
for standard sandwich ELISA assays to measure the IFN-
 
 
 
 or IL-4
cytokine production as described (40). Proliferation was assayed by
addition of 1 
 
 
 
Ci [
 
3
 
H]TdR (ICN Biomedicals) for the last 16 h of
a 5 d culture. Cells were harvested and uptake of radioactivity was
measured with the Betaplate reader (PerkinElmer).
 
Induction and Clinical Evaluation of EAE.
 
Female mice, 6–15
wk of age were immunized once subcutaneously with 100 or
300 
 
 
 
g of MBP or MOG35–55 peptide emulsified in IFA
(DIFCO) supplemented with attenuated 
 
M. tuberculosis
 
 (DIFCO)
to 5 mg/ml. 0.15 
 
 
 
g of pertussis toxin (PTx; List Biological Lab-
oratories, Inc.) was injected twice in 200 
 
 
 
l saline intraperito-
neally 24 and 72 h later. Mice were observed daily for signs of
EAE for 30 to 50 d. The average disease score for each group
was calculated by averaging the maximum severity of all of the
affected animals in the group. Also, the maximum disease score
of each animal is given in the parentheses. Disease severity was
scored on a 5-point scale, as described earlier (31): 1, flaccid tail;
2, hind limb weakness; 3, hind limb paralysis; 4, whole body pa-
ralysis; 5, moribund or death.
 
Immunization with
 
 
 
 
 
-GalCer or 
 
 
 
-GalCer.
 
 In the coimmuniza-
tion protocol, 4.4 
 
 
 
g of 
 
 
 
-GalCer dissolved in 200 
 
 
 
l PBS was
given intraperitoneally at the time of EAE induction. For the
prior-immunization protocol, 4.4 
 
 
 
g of 
 
 
 
-GalCer in 200 
 
 
 
l of
either PBS or vehicle was given (either three times, 1 wk apart,
or once as indicated) 1 wk before the induction of EAE. In some
experiments, 4.4 
 
 
 
g of 
 
 
 
-GalCer in 200 
 
 
 
l of vehicle was in-
jected as control.
 
Liver Mononuclear Cell Purification.
 
Liver monocytes were iso-
lated as described previously (39). For purification of liver mono-
cytes, liver was excised after perfusion through the left ventricle
of the heart. Liver tissue was then pressed through a 70-
 
 
 
m cell
strainer (Becton Dickinson) in RPMI 1640 (Hyclone) supple-
mented with 5% FCS equilibrated to room temperature before
use. Liver cells were suspended in 40% isotonic Percoll (Amer-
sham Pharmacia Biotech) underlaid with 60% isotonic Percoll,
and spun for 25 min at 900 
 
g
 
 at room temperature. The fat layer
and the bottom layer of 60% Percoll solution were discarded.
Cells in the remaining layer were washed twice to remove Per-
coll before use.
 
Results
 
Characterization of NK T Cells in B10.PL (H-2
 
u
 
) Mice.
 
NK T cells from B10.PL mice were characterized for the
expression of various cell surface markers and for their acti-
vation in vitro and in vivo in response to the glycolipid
 -GalCer. Single cell suspensions from liver and spleen of
B10.PL mice were stained for typical markers associated
with NK T cells as well as with mCD1d-tetramers loaded
with  -GalCer and analyzed by flow cytometry. In parallel,
mice were injected with  -GalCer or vehicle and 4 h later
assessed for the presence of NK T cells in the liver and
spleen. The flow cytometry profiles of lymphocytes stained
with a pan-TCR V  chain antibody and with either the
NK1.1 marker or the mCD1 tetramer loaded with  -Gal-
Cer are shown in Fig. 1. The percentages of different pop-
ulations in vehicle or  -GalCer–immunized mice are com-
piled in Table I. Similar to the data reported in C57BL/6
mice (39), NK T cells in B10.PL mice are NK1.1  and
constitute 20–30% of cells in the liver and 1–2% in the
spleen. The majority of liver NK T cells stain with  -Gal-
Cer tetramer and predominantly utilize TCR V 8.2, V 7,
and V 2 gene segments. They display an activated memory
T cell phenotype since they are CD44 , CD69 , and
CD62L  (unpublished data).
The kinetics of  -GalCer–dependent activation and
subsequent depletion of NK T cells in B10.PL mice is also
similar to that reported in C57BL/6 mice (39). As shown
in Fig. 1 and Table I, most tetramer-reactive NK T cells in
the liver disappear within 4 h after injection with  -Gal-
Cer. As splenic NK T cells from naive mice proliferate in
Table I. Cell Surface Markers Expressed by the NK T Cell 
Population in B10.Pl Mice
Spleen Liver
Markers PBS  -GalCer PBS  -GalCer
MCD1d-tetramer 2.56 1.78 18.67 0.1
MCD1d-tetramer plus TCR 1.78 1.41 22.65 1.54
NK1.1 3.37 3.22 41.62 36.96
NK1.1 plus TCR 1.39 0.8 21.83 0.92
NK1.1 plus V 8.1/2 0.11 0.05 10.64 1.77
NK1.1 plus V 7 0.8 0.53 4.13 0.38
NK1.1 plus V 2 0.05 0.11 2.36 n/d
Unloaded tetramer 1.02 1.08 0.65 0.44
Monocytes from the liver and spleens of each PBS or  -GalCer
immunized mouse were stained and analyzed by flow cytometry as
described in Materials and Methods. These data are representative of
two independent experiments.
Figure 1. Flow cytometry profiles of the NK T cell population in
B10.PL mice immunized either with PBS or  -GalCer. Mononuclear
cells from the livers and spleens of mice immunized with PBS or with
 -GalCer were stained with PE-labeled mCD1d/ -GalCer tetramers or
with PE-labeled anti-NK1.1 antibodies in combination with FITC-
labeled pan anti-TCR V  mAb. Numbers indicate the percentage of
NK.1.1 TCR V   or tetramer TCR V   cells in individual mice.
These data are representative of two independent experiments.1792 Modulation of EAE by Activation of NK T Cells
response to in vitro challenge with  -GalCer, we wanted
to examine their proliferative response in mice at different
times following a single injection of  -GalCer. As shown
in Fig. 2 B, proliferative responses to  -GalCer are absent
in mice injected 3 and 5 d earlier. However, by day 10
proliferation is partially restored, suggesting reconstitution
of the NK T cell population. Next we compared in
vitro proliferation and cytokine production in response to
 -GalCer in both B10.PL and C57BL/6 mice. As shown
in Fig. 2 A, proliferative response and IFN-  secretion
were very similar in both mice. However a significant dif-
ference between the strains was found in IL-4 secretion,
which was significantly reduced in B10.PL compared with
C57BL/6 mice.
Coimmunization of  -GalCer and MBP Results in Skewing
of Anti-MBP Response Toward Th1 in B10.PL Mice. As
the cytokine microenvironment is one of the crucial factors
in differentiation of naive CD4 T cells in a type 1 or 2 di-
rection, we wanted to determine whether rapid secretion
of both IFN-  and IL-4 after activation of NK T cells by
 -GalCer can influence the anti-MBP T cell response.
Groups of B10.PL mice were injected intraperitoneally
with 4.4  g of  -GalCer in vehicle or with vehicle only
and simultaneously with a subcutaneous immunization of
100  g MBP emulsified in CFA. 10 d later draining lymph
nodes were assayed for proliferation and cytokine produc-
tion in response to an in vitro challenge with the dominant
determinant of MBP, Ac1–9 (Fig. 3). Although there
was no significant difference in the proliferative recall
with Ac1–9, IFN-  secretion was enhanced 4–5-fold by
MBPAc1–9–reactive T cells in the animals coimmunized
with  -GalCer. There was no detectable difference in the
secretion of IL-4 in these cultures. Proliferative responses
and cytokine production in response to purified protein
derivative of mycobacterium (PPD) were comparable in
both groups of mice (proliferation ranged from 65,765 to
128,392 cpm, while IFN-  levels were from 2,033–3,500
pg/ml). These data suggested that activation of NK T cells
at the time of priming of MBP-reactive T cells in B10.PL
mice results in further skewing of the anti-MBP response
toward a predominant Th1 phenotype.
Coimmunization of  -GalCer with MBPAc1–9 Exacerbates
EAE in B10.PL Mice. Generally, further polarization of
MBPAc1–9–reactive T cells toward the Th1 phenotype
exacerbates EAE, while their Th2 polarization ameliorates
clinical signs of the disease (36, 37). As we found further
Th1-skewing of the MBP response following coimmuniza-
tion with  -GalCer and MBP, we next examined whether
the course of EAE is altered. Groups of B10.PL mice were
injected intraperitoneally with  -GalCer in vehicle or with
vehicle alone and at the same time immunized with
MBPAc1–9/CFA/PT for the induction of EAE and moni-
Figure 2. In vitro response of splenocytes to  -GalCer. (A) Spleno-
cytes from naive B10.PL, C57BL/6, and C57BL/6.CD1 /  mice were
cultured with graded concentrations of  -GalCer for measurement of
proliferation and cytokine secretion. Proliferative response and IFN-  se-
cretion is shown in individual mice. A representative of three experiments
is shown. (B) Groups of B10.PL mice (two in each group) were immu-
nized either with  -GalCer or with vehicle, and proliferation in response
to an in vitro recall with 100 ng of  -GalCer was determined 3, 5, or 10 d
later. Proliferative responses in individual mice are shown. These data are
representative of two independent experiments.1793 Jahng et al.
tored daily for clinical paralysis. As shown in Fig. 4 and Ta-
ble II, the control (vehicle/PBS) group had a normal dis-
ease course with an average disease score of 2.9 and a
mean day of onset 13.2 d after Ac1–9 immunization. In the
 -GalCer–immunized group, mice contracted much more
severe and chronic EAE with an average disease score of
4.5. 1 in 10 mice died from paralysis in the control group
whereas 5/8 mice did not recover and died from EAE in
the  -GalCer–coimmunized group. Thus activation of NK
T cells with  -GalCer concomitant with the MBP/Ac1–9-
immunization results in exacerbated disease.
Preimmunization with  -GalCer Results in Decreased Secre-
tion of IFN-  by MBP-reactive T Cells and Prevention of EAE
in B10.PL Mice. As shown in Fig. 1 and Table I, most
NK T cells disappear after a single injection with  -Gal-
Cer. Furthermore, previous studies have shown that multi-
ple injections of  -GalCer in C57BL/6 mice results in an
enhanced production of IL-4 by the remaining population
of T cells (26). Similarly multiple injections of  -GalCer
protects NOD mice from diabetes (41–43). To determine
whether the timing of the NK T cell activation (coimmu-
nization versus preimmunization with  -GalCer) is impor-
tant in modulating EAE, two sets of experiments were per-
formed. In the first set, groups of mice were given a single
injection of  -GalCer 5–7 d before MBPAc1–9/CFA/PT
challenge. In the second set, groups of mice were given
three weekly injection of  -GalCer and 1 wk after the last
injection, they were challenged with MBPAc1–9/CFA/
PT for induction of EAE. All mice were monitored for
symptoms of disease daily. As shown in Fig. 5, A and B,
and Table II, both  -GalCer preimmunized groups of
mice contracted monophasic disease of less severity (mean
disease score of 1.2 in mice immunized once and 0.7 in
mice immunized three times) in comparison to mice in the
Figure 3. Coimmunization of  -GalCer with MBP promotes antigen-
specific Th1 responses in B10.PL mice. Groups of B10.PL mice (two in
each) were immunized either with  -GalCer or with PBS/vehicle at the
time of challenge with MBP emulsified in CFA. 9 d later lymph node
cells were cultured with graded concentrations of MBPAc1–9. Prolifera-
tion (A) and IFN-  secretion (B) are shown. IL-4 production was below
the level of detection, and response to PPD was similar in both groups of
mice. These data are representative of two independent experiments.
Figure 4. Coimmunization of  -GalCer with MBP exacerbates EAE in
B10.PL mice. EAE was induced following the coimmunization protocol
as described in Materials and Methods. The mean clinical disease course of
mice (four in each group) in both vehicle and  -GalCer–immunized
groups is shown. These data are representative of two independent exper-
iments. A summary of all independent experiments is provided in Table II.
Table II. Modulation of EAE by  -GalCer in B10.PL Mice
Treatment
No. animals with
EAE/total no. of animals
(individual maximal score)
Mean 
disease
score
Mean
day
of onset
Vehicle/PBS 9/10 (5,4,4,4,3,3,3,2,1,0) 2.9 13.2
Coimmunization
with  -GalCer 8/8 (5,5,5,5,5,4,4,3) 4.5 12.3
Preimmunization
with  -GalCer (1 ) 4/8 (4,3,1,1,0,0,0,0) 1.1 11.5
Preimmunization
with  -GalCer (3 ) 3/9 (4,1,1,0,0,0,0,0) 0.7 13.2
Preimmunization
with  -GalCer (1 ) 4/4 (4,3,3,3) 3.2 12.7
Preimmunization
with  -GalCer (3 )
plus anti-IL-4 6/6 (5,4,4,3,3,3) 3.3 11.2
Preimmunization
with  -GalCer (1 )
plus control Ig 3/4 (2,1,1,0) 1.1 11.7
Groups of age-matched B10.PL mice were subcutaneously injected
with MBPAc1-9/CFA/PT for the induction of EAE and immunized
intraperitoneally with glycolipids in the vehicle or with vehicle only,
according to coimmunization or preimmunization protocols described
in Material and Methods. For the depletion of IL-4, a neutralizing anti-
IL-4 monoclonal antibody 11B11 (1 mg/mouse) or a control Rat Ig was
administered. Clinical symptoms of EAE were monitored daily.1794 Modulation of EAE by Activation of NK T Cells
control group with mean disease score of 2.9. In contrast,
prior immunization of B10.PL mice with  -GalCer which
binds to CD1d but does not activate NK T cells, has a
negligible influence on the course of EAE (Table II). Thus,
coimmunization exacerbates disease while preimmuniza-
tion significantly suppresses EAE. It is apparent that the
timing of activation of NK T cells by  -GalCer affects
the nature of the modulation of EAE. Next we examined
the secretion of IFN-  and IL-4 by MBPAc1–9–reactive
T cells in mice coimmunized or preimmunized with
 -GalCer. As shown in Fig. 6, while there was a signifi-
cant decrease in the secretion of IFN-  by MBPAc1–9–
reactive T cells in the preimmunized group, IL-4 secretion
was moderately enhanced, compared with the coimmu-
nized group of animals. These data suggest that prior acti-
vation of NK T cells by  -GalCer prevents EAE by de-
creasing IFN-  secretion and enhancing IL-4 secretion by
the subsequent anti-MBP response.
 -GalCer–mediated Exacerbation and Protection from EAE Is
Lost in Mice Deficient in IFN-  and IL-4, Respectively. As
shown in Figs. 3 and 6, while coimmunization of  -Gal-
Cer with MBP enhances IFN-  secretion, preimmuniza-
tion leads to decreased IFN-  and moderately enhanced
IL-4 secretion by MBP-reactive T cells. We have used
B10.PL-IFN-  /  and anti–IL-4–treated B10.PL mice to
examine the role of IFN-  and IL-4 in  -GalCer–medi-
ated potentiation and protection from EAE, respectively.
MBP-induced EAE in B10.PL-IFN-  /  mice is usually
lethal, and nearly all mice fail to recover and die from pa-
ralysis. The NK T cell population and its activation/deple-
tion kinetics was characterized in these mice and found to
be similar to the wild type B10.PL mice (unpublished data).
As shown in Fig. 7, coimmunization of  -GalCer with
MBPAc1–9 in B10.PL-IFN-  /  mice fails to potentiate
EAE. In fact  -GalCer–treated mice contracted less severe
disease (mean disease score 3.1), compared with mice in
the control group (mean disease score, 4.9). 9 out of 10
mice died from paralysis in the control group, whereas
5/10 mice succumbed to death in the  -GalCer–coimmu-
Figure 5. Preimmunization with  -GalCer protects B10.PL mice from
EAE. EAE was induced following the preimmunization protocol as de-
scribed in Materials and Methods. Groups of mice (four in each) were im-
munized either once (A) or three times (B) with  -GalCer, and 1 wk af-
ter the last immunization, they were immunized with MBP/CFA/PT for
the induction of EAE. A summary of all independent experiments is
given in Table II.
Figure 6. Preimmunization with  -GalCer decreases IFN-  produc-
tion and increases IL-4 production by MBPAc1–9–reactive T cells in
B10.PL mice. Groups of B10.PL mice (two in each) were immunized ei-
ther with  -GalCer or with PBS three times, 1 wk apart, 1 wk before
challenge with MBPAc1–9 emulsified in CFA. 9 d later lymph node cells
were cultured with Ac1–9 and supernatants were collected 48 h later for
cytokine secretion. These data are representative of three experiments.
Figure 7. IFN-  is required for the  -GalCer-mediated potentiation
of EAE in B10.PL mice. Groups of B10.PL.IFN-  /  (four in each) were
coimmunized for EAE with MBPAc1–9 and  -GalCer as described in
Materials and Methods. Mean clinical disease scores in both vehicle and
 -GalCer immunized groups are shown. These data are representative of
two independent experiments.1795 Jahng et al.
nized group. To examine the involvement of IL-4 in pro-
tecting mice against EAE using the preimmunization pro-
tocol, groups of B10.PL mice were injected with anti–IL-4
mAb (11B11, 1 mg per mouse) or control Ig (Table II).
The protective effect of prior immunization with  -Gal-
Cer was lost in the absence of IL-4 in vivo. These data in-
dicate that  -GalCer–dependent potentiation and protec-
tion of EAE is mediated by IFN-  and IL-4, respectively.
Both the Potentiating and Protective Effects of  -GalCer Im-
munization on EAE Require CD1d Antigen Presentation. As
prior immunization of B10.PL mice with  -GalCer, which
binds to CD1d but does not activate NK T cells, has negli-
gible influence on the course of EAE (Table II), we wanted
to determine whether modulation of EAE by  -GalCer re-
quires the CD1d antigen presentation pathway. We have
generated B10.PL.CD1d /  and B10.PL.CD1d /  mice
by backcrossing CD1d-deficient C57BL/6 mice onto the
B10.PL strain. As shown in Fig. 8, coimmunization (A) or
preimmunization (B) with  -GalCer had no effect on the
course of disease in B10.PL.CD1d /  mice and clinical
symptoms of EAE in both vehicle- and  -GalCer–immu-
nized mice were very similar. These data provide strong
evidence that potentiation or protection from EAE by
 -GalCer is mediated by the CD1d-dependent activation
of V 14  NK T cells.
Coimmunization of  -GalCer with MOG35–55 Prevents
EAE in C57BL/6 Mice. As shown in Fig. 2, IL-4 produc-
tion in splenocytes from C57BL/6 mice in response to an
in vitro stimulation with  -GalCer is more pronounced
than in B10.PL mice. As C57BL/6 is relatively resistant to
MBP-induced EAE, we have tested whether coimmuniza-
tion of  -GalCer with MOG35–55 is able to influence the
disease course. Groups of C57BL/6 mice were injected in-
traperitoneally with  -GalCer in vehicle or with vehicle
alone and at the same time immunized with MOG35–55/
CFA/PT for the induction of EAE. As shown in Fig. 9 and
Table III, mice in the  -GalCer–immunized group were
significantly protected from EAE: 9/10 mice in the vehicle-
immunized group contracted severe disease (mean disease
score 3.1), whereas 2/10 mice developed milder disease
(mean disease score 0.3) in the  -GalCer–treated group.
Furthermore   -GalCer-mediated prevention of EAE in
C57BL/6 mice also requires the CD1d presentation path-
way, as the course of EAE in CD1d-deficient mice is not
influenced by coimmunization with  -GalCer (Table III).
It is interesting that the anti-MOG response in C57BL/6
mice following coimmunization with  -GalCer becomes
skewed in a Th2 direction (43a; and data not shown).
Discussion
EAE in the B10.PL mouse represents one of the best-
characterized models of antigen-induced T cell–mediated
autoimmune disease. Although a great deal is known about
different myelin antigens, autoreactive T cells, and cyto-
kines involved in the pathogenesis of EAE in these animals,
little is known about the role of NK T cells. Here we have
demonstrated that activation of V 14 NK T cells by  -Gal-
Cer in the context of CD1d alters the cytokine profile of
T cells reactive to myelin antigens and their ability to in-
Figure 8. Potentiation and protection from EAE by  -GalCer in
B10.PL mice are dependent upon the CD1d antigen presentation path-
way. Groups of B10.PL.CD /  mice (six in each) were injected with
 -GalCer and MBP following the coimmunization (A) or prior-immu-
nization (B) protocol as described in Materials and Methods. The mean
clinical disease scores in each group are shown.
Figure 9. Coimmunization of  -GalCer with MOG35–55 prevents
EAE in C57BL/6 mice. Groups of BL/6 mice (four in each) were immu-
nized with MOG35–55 peptide for EAE induction following the coimmu-
nization protocol with  -GalCer. The mean clinical disease scores for
both vehicle and  -GalCer immunized groups are shown. Summary of all
experiments is provided in Table III. Monocytes from the liver and
spleens of each PBS or  -GalCer immunized mouse were stained and an-
alyzed by flow cytometry as described in Materials and Methods. These
data are representative of two independent experiments.1796 Modulation of EAE by Activation of NK T Cells
duce EAE. Interestingly, administration of  -GalCer can
either potentiate or prevent disease, depending upon the
nature of the NK T cell response in the strain examined.
While IFN-  secretion is involved in exacerbation, IL-4
plays an important role in protection. These findings sug-
gest that NK T cells play an important role in the patho-
genesis of EAE and that these cells are useful targets for in-
tervention in autoimmune diseases of the CNS.
Do NK T cells play a role in the pathogenesis of EAE or
MS in the absence of lipid immunization? Earlier observa-
tions have suggested low numbers of NK T cells in EAE-
susceptible SJL/J mice (22). Consistent with this idea, it has
been recently reported that a significant decrease in the
V 24J Q NK T cell population occurs during clinical re-
mission in MS, but not in autoimmune/inflammatory dis-
eases affecting peripheral nerves or in chronic inflamma-
tory demyelinating polyneuropathy (14). It is interesting
that the severity of EAE in both C57BL/6.CD1d /  (H2b)
and B10.PL.CD1d /  (H-2u) mice is reduced in compari-
son to wild-type mice. Furthermore, we have found the
presence of CD1d- -GalCer tetramer  T cells in CNS-
infiltrates during the normal course of EAE in animals in-
jected with MBPAc1–9 in the absence of  -GalCer (un-
published data). Thus, NK T cells are potentially involved
in pathogenesis of autoimmune demyelination and could
have a positive or negative influence. A recent demonstra-
tion related to the presence of NK1.1 , DX5  T cell pop-
ulation and its regulatory role in EAE is consistent with
this notion (44). In diabetes patients IL-4 secretion by NK
T cells has been found to be defective (13). These observa-
tions further suggest a potential role of NK T cells in au-
toimmune conditions in humans.
C57BL/6 mice are relatively resistant to MBP-induced
EAE. CD1d-restricted NK T cells in EAE-susceptible
B10.PL (H-2u) and relatively resistant C57BL/6 (H-2b)
mice are very similar with respect to cell number and TCR
usage. As in C57BL/6 mice, NK T cells in B10.PL mice
predominantly utilize the TCR V 8.2 gene segment. After
in vivo activation with  -GalCer, V 14  NK T cells in
B10.PL mice using all V  gene segments disappear in a
similar fashion as reported by others (39). However, al-
though there is no significant strain difference in prolifera-
tion or in IFN-  production in response to  -GalCer, IL-4
secretion is much lower in splenocytes from B10.PL mice
in comparison to C57BL/6 mice. This difference in IL-4
secretion upon CD1d-dependent recognition of  -GalCer
does not appear to be related to MHC difference, as in an-
other H-2u strain, PL/J, IL-4 secretion levels are similar to
those in C57BL/6 (unpublished data). Our data has shown
that coimmunization of  -GalCer with MBP in B10.PL
mice results in further skewing of the anti-MBP response
toward Th1 and exacerbation of EAE, whereas coimmuni-
zation of  -GalCer with MOG35–55 protects C57BL/6
mice from disease. Our preliminary data and the accompa-
nying paper (43a) suggest that protection is mediated by
immune deviation of the anti-MOG response. In both
strains, prior immunization with  -GalCer leads to reduced
IFN-  secretion and increased IL-4 secretion by MBP-
reactive T cells and subsequent protection from EAE. Col-
lectively, these data suggest that the balance between IFN- 
and IL-4 secretion in response to  -GalCer determines
whether the activation of V 14  NK T cells will enhance
or diminish disease.
It is well established that invariant V 14  NK T cells
rapidly secrete IFN-  as well as IL-4 upon stimulation in
vitro and in vivo (3–5).  -GalCer-activated NK T cells
also activate NK cells, B cells and dendritic cells as well as
conventional T cells (27, 45–48). Consistent with their se-
cretion of both IFN-  and IL-4, NK T cells have been im-
plicated in either augmenting or suppressing antitumor
responses (7–9). Similarly NK T cells also have been impli-
cated in effective immunity against pathogens (6, 49, 50). It
has been suggested that IFN-  secretion by NK cells is de-
pendent upon the activation of NK T cells (45). It is possi-
ble that in B10.PL mice  -GalCer administration activates
NK T cells followed by activation of NK cells, which con-
tributes to the early IFN- –rich milieu, thus skewing the
MBP response toward Th1 and the potentiation of EAE.
Table III. Modulation of EAE by  -GalCer in C57BL/6 and C57BL/6.CD1d /  Mice
Treatment
No. animals with
EAE/total no. of animals
(individual maximal score) Mean disease score Mean day of onset
C57BL/6 mice
Vehicle/PBS 9/10 (5,5,4,4,4,4,3,1,1,0) 3.1 14.4
Coimmunization with  -GalCer 2/10 (2,1,0,0,0,0,0,0,0,0) 0.3 13.5
C57BL/6.CD1d /  mice
Vehicle/PBS 10/12 (4,3,3,3,3,2,2,2,1,1,0,0) 2.0 14.9
Coimmunization with  -GalCer 7/8 (4,3,2,2,2,2,1,0) 2.0 16.6
Groups of age-matched mice were subcutaneously immunized with 300  g of MOG35–55 emulsified in CFA and at the same time administered
with 4.4  g of  -GalCer in vehicle or with the vehicle only, as described in Materials and Methods. Clinical symptoms of EAE were monitored daily.1797 Jahng et al.
Our observation that the loss of potentiation of EAE in
mice deficient in either IFN-  or in the CD1d pathways of
antigen presentation indicates that even if NK cells eventu-
ally may become involved, the initial response is mediated
by V 14  NK T cells.
The role of IL-4 in  -GalCer–mediated protection from
EAE is clearly highlighted by the fact that prior immuniza-
tion with the lipid is protective in the presence but not in
the absence of IL-4. It is likely that IL-4 secretion by both
NK T and MBP-reactive T cells is important for preven-
tion of EAE. Although IL-4 is involved in this protection,
it is not yet clear whether repeated immunization polarizes
NK T cells for the production of IL-4, as suggested by ear-
lier data (26). Our findings do not support this possibility,
as when the final  -GalCer injection of a series is given at
the same time as MBP immunization, B10.PL mice still de-
velop exacerbated EAE (unpublished data). If NK T cells
themselves were deviated to produce IL-4, their activation
should deviate the anti-MBP response and protect mice
from disease. It remains possible that repeated activation of
NK T cells alters antigen-presentation in vivo. We are cur-
rently investigating the mechanism by which repeated in-
jection of  -GalCer deviates the anti-MBP response.
Our data collectively suggest that the mode of activation
of NK T cells by  -GalCer is decisive in determining the
Th1/Th2 balance among MBP-reactive T cells and hence
their ability to cause EAE. Therefore for intervention in
Th1-mediated autoimmune conditions, it may be desirable
to activate NK T cells by other lipid ligands or by altered
lipid ligands in a manner that enhances secretion of IL-4.
For example, it has recently been shown that NK T cells
predominantly secrete IL-4 upon activation with an altered
 -GalCer molecule containing truncated sphingosine resi-
dues (51). The potential therapeutic value of targeting NK
T cells for treatment of autoimmune conditions has also re-
cently been shown in NOD mice, where administration of
 -GalCer results in immune deviation of the anti-islet re-
sponse and protection from diabetes (41–43).
As CD1d molecules, unlike classical MHC molecules,
are nonpolymorphic and are remarkably conserved among
different species, insight into the role of the NK T cell
population will be extremely valuable in the development
of HLA-independent therapeutic approaches for autoim-
mune conditions. Therefore studies of the role of lipid-
reactive T cells and their modulatory influence on adaptive
immunity has implications for the pathophysiology as well
as for the development of potential therapies for interven-
tion in T cell–mediated diseases.
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